Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants.

GlobeNewsWire • Feb 10, 2026

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).

GlobeNewsWire • Feb 5, 2026

Strata Critical Medical: Likely Valuation Re-Rating After Q4 Earnings (Upgrade)

Strata Critical Medical, Inc. is refocused on organ transplant logistics after divesting its air passenger business, positioning for higher-margin, long-term growth. SRTA's acquisition of Keystone Perfusion fills a key service gap, boosting market share to 13% and enabling full-stack, technology-agnostic offerings in organ preservation. Keystone's strong FCF conversion (80%) and rapid revenue growth (45% YoY) are expected to drive SRTA's margin expansion and profitability from 2026 onward.

Seeking Alpha • Jan 29, 2026

Strata Critical Medical, Inc. (SRTA) Analyst/Investor Day Transcript

Strata Critical Medical, Inc. ( SRTA ) Analyst/Investor Day November 17, 2025 2:00 PM EST Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance Melissa Tomkiel - Co- CEO, General Counsel & Director William Heyburn - Co- CEO, CFO & Director Scott Wunsch - Chief Executive Officer of Trinity Keith Trepanier - Chief of Safety Andrew Marreel Louis Verdetto Michael Hancock Scott Silvestry Jamie Bucio Christie Campbell Eric Moore Conference Call Participants Xuesong Wang - Morgan Stanley, Research Division Presentation Mathew Schneider Vice President of Investor Relations & Strategic Finance All right. Let's get started.

Seeking Alpha • Nov 21, 2025

Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company") is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. The event features presentations by leaders across the business and begins at 2:00pm ET.

GlobeNewsWire • Nov 17, 2025

Strata Critical Medical, Inc. (SRTA) Q3 2025 Earnings Call Transcript

Strata Critical Medical, Inc. ( SRTA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance William Heyburn - Co- CEO, CFO & Director Melissa Tomkiel - Co- CEO, General Counsel & Director Conference Call Participants Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jon Hickman - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Strata Critical Medical Fiscal Third Quarter 2025 Earnings Release Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Seeking Alpha • Nov 10, 2025

Strata Critical Medical Announces Third Quarter 2025 Results

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition  Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year period Medical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition (1) Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025 (1) Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range Investor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

GlobeNewsWire • Nov 10, 2025

Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.

GlobeNewsWire • Oct 9, 2025

Strata Announces 2025 Investor Day

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), will hold an Investor Day at the Nasdaq MarketSite in New York City on Monday, November 17th 2025. The event will begin at 2:00pm ET and will include presentations by members of the management team.

GlobeNewsWire • Sep 30, 2025

OrganOx metra® Receives FDA Approval for Operation During Air Transport, Expanding Access to Life-Saving Liver Perfusion Technology

OrganOx Ltd., the organ technology company tackling the world's toughest transplant challenges, announced that its metra® normothermic machine perfusion (NMP) device has received approval from the U.S. Food and Drug Administration (FDA) for operation during air transport. This marks a major milestone in the company's mission to make every organ count by supporting the broader utilization of donor organs that might otherwise be discarded due to time, geographic distance or marginal liver function1,2.

GlobeNewsWire • Sep 18, 2025